China Medical's HER-2 FISH breast cancer test approved in China
This article was originally published in Clinica
China Medical Technologies' breast cancer HER2 FISH probe has been approved by the Chinese state FDA (SFDA). It is the first fluorescence in situ hybridisation (FISH) probe to get the go-ahead in the country, the Beijing-based company claims. FISH can detect amplification of the HER2 gene status and be used to tailor treatment – Roche's HER2-targeting drug Herceptin (trastuzumab) is effective in those with HER2-positive cancer. China Medical launched a FISH test for prostate cancer in July 2008 (see Clinica No 1302, p 12).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.